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Increased immune cell infiltration in patient-derived
tumor explants treated with Traniplatin: an original
Pt(IV) pro-drug based on Cisplatin and Tranilast†
Daniele Lo Re, *a Diego Montagner, *b Dina Tolan,c Claudio Di Sanza,a
Mar Iglesias,de Alexandre Calon *d and E. Giralt af
Elevated intra-tumoral immune infiltrate is associated with an
improved prognosis in cancer of distinct origins. Traniplatin (TPT)
is a novel platinum(IV) pro-drug based on Cisplatin (CDDP) and the
marketed drug Tranilast. When compared in vitro to Cisplatin, TPT
showed increased cytotoxic activity against colon and lung cancer
cells but decreased activity against immune cells. In addition, TPT
efficiency was evaluated in tumor explants derived from colorectal
cancer samples from patients subjected to intended curative
surgery. TPT induced strong intra-tumoral cytotoxic activity yet
was associated with an elevated presence of immune cell infiltrate,
suggesting a reduced cytotoxic activity against immune cells in
colorectal cancer.
Colorectal cancer (CRC) is considered to be the third most
common cancer and the fourth leading cause of cancer death
worldwide.1 5-FU in combination with oxaliplatin (FOLFOX)
represents the standard of care for CRC. However, many
patients do not respond to FOLFOX or only show a marginal
improvement.2 Hence, CRC incidence and mortality are predicted
to increase unless new therapies are discovered.3 CDDP (Cisplatin 2,
Scheme 1) is commonly used for the treatment of several cancers
including colon,4 testicular, ovarian, lung, head and neck.5,6 The
benefit of platinum therapies is often counterbalanced by the
appearance of severe side effects.5 Thus, the development of
stable platinum Pt(IV) complexes that can mitigate some of these
limitations has gained significant attention. Pt(IV) species could
overcome the high toxicity of Pt(II)-based drugs7,8 due to
increased stability compared to the corresponding Pt(II) species.9
In addition, Pt(IV) complexes can get to the cancer cellular environ-
ment without reacting with sulfur-containing biomolecules, which
are the main cause of nephrotoxicity.10 One example is Satraplatin,
an orally administrated Pt(IV) complex that has reached phase III
trials.11 Pt(IV) pro-drugs are reduced inside the cell to the corres-
ponding Pt(II) species, with the release of the axial ligands.12 The
intracellular reduction has been demonstrated by XANES spectro-
scopy and fluorescence techniques.13–15 It has been reported that
the physicochemical properties of Pt(IV) complexes, such as
aqueous solubility or lipophilicity, can be tuned by modification
of the axial substituents.16 Tranilast is commercialized as an anti-
allergy drug used for the treatment of inflammatory diseases.17
Tranilast (3) also reduces pathological fibrosis associated with
myocardial infarction,17 inhibits human breast cancer cell
migration17 and has raised interest for its properties as a cyto-
static agent in prostate, breast and pancreatic cancer as well as in
glioma and other tumors.18 Furthermore, Tranilast is a relatively
safe drug with modest side effects. At doses of 600 mg day1, it is
well tolerated by patients over a period ofmonths.17 Themechanism
by which Tranilast acts as an anti-proliferative drug is still debated.
Some data suggest that it suppresses the TGF-b pathway.17,18 How-
ever, other mechanisms have been proposed17 such as inhibition of
MMP-2/9 production, inhibition of the EMT and suppression of the
activation of NF-kB, protein kinase C (PKC) and MAPKs.
Here we report the synthesis, characterization and a deep
biological evaluation of Traniplatin (TPT), a new Pt(IV) pro-drug
with Tranilast in the axial position (Scheme 1).
Tranilast (3) was successfully conjugated to CDDP (2) by
reacting oxoplatin19 (4) with the NHS-ester derivative of Tranilast (5)
Scheme 1 Traniplatin (TPT, 1), Cisplatin (CDDP, 2), Tranilast (3) and
compound 4.
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(see Synthesis, ESI†). The new Pt(IV) derivative TPT (1) was
characterized using elemental analysis, 1H, 13C and 195Pt
NMR, and HPLC (Fig. S1–S6, ESI†). Unfortunately, attempts to
synthesize the bis-adduct were unsuccessful. Since the mechanism
of action of Pt(IV) pro-drugs requires their intracellular reduction to
the corresponding Pt(II) species with release of the axial ligands,
TPT reduction was studied via HPLC and it was completely
reduced by ascorbic acid with Tranilast release in 30 hours
(Fig. S7, ESI†). TPT is stable for up to 24 h in aqueous/ACN
solution (Fig. S8, ESI†).
Biological activity. The sensitivity of cancer cells to the newly
synthesized TPT was evaluated on a panel of different cancer
cell lines, such as in human-originating prostate (PC-3 and
C4-2), cervical (HeLa), colorectal (HT29) and lung (A549) cancer
cell lines. TPT efficiency was compared to CDDP, Tranilast (3)
and to a mixture (1 : 1 ratio) of CDDP and Tranilast (3). Prostate
and cervical cancer cells where treated with increasing con-
centrations of TPT, demonstrating cytotoxic activity in line with
that of CDDP (Fig. 1a).
Interestingly, TPT was found to be 4-fold more potent than
CDDP in lung cancer cells and 10 times more cytotoxic than
CDDP in CRC cells, suggesting a specific affinity of TPT for lung
and colon cancer cells (Fig. 1a). Of note, the free axial ligand
Tranilast (3) only showed weak activity against all of the treated
cancer cell lines in our experimental setting. We next analyzed the
capacity of TPT to induce cancer cell death. To this end, caspase-3/7
activation – an essential step of apoptosis – was measured in treated
cancer cells. An optimal experimental setting was defined for each
cancer cell line. As shown in Fig. 1b, incubation of lung cancer cells
(A549) and colon cancer cells (HT29) for 24 h cells with TPT (10 mM)
resulted in a significantly higher activation of caspase-3/7 compared
to that of the CDDP treatment. Increased accumulation of an
active platinum species may result in enhanced cytotoxicity.
Cellular uptake of a platinum drug could be influenced by the
overall lipophilicity of a specific platinum drug. It has been
described previously that the introduction of simple ligands20
results in increased platinum cellular-uptake associated with an
enhanced cytotoxic activity. The lipophilicity index logPow value
determined for TPT was 0.41  0.09, which is in line with
previous data reported for similar compounds16 and is higher
than the logPow of CDDP (2.03  0.47).16 Since the higher
lipophilicity of TPT could explain its enhanced biological
activity,16 we speculated that a Pt(IV) compound with a similar
logPow may show a comparable biological activity. We therefore
synthesized compound 4 (Fig. 2) which is reported to have a
logPow comparable to that of TPT (0.46 0.04 vs.0.41 0.09
respectively).16 Surprisingly, compound 4 was less cytotoxic than
TPT in A549 and HT 29 cells [compound 4: IC50 = 6.3 mM (A549)
and 34.8 mM (HT29) vs. TPT: 0.5 mM (A549) and 4.7 mM (HT29)].
The reduced activity of 4 could be explained by a decreased
Pt(IV) internalization together with a slow reduction rate and a
reduced release of the cytotoxic Pt(II) species.
We therefore investigated the intracellular platinum accumula-
tion of TPT, CDDP and compound 4 using ICP-MS. A549 andHT29
cells were adhered to a multiwell plate surface and exposed to
CDDP, TPT and compound 4 at a concentration of 10 mM. Pt
uptake was measured following a 4 h treatment. As expected, the
cells treated with TPT showed a platinum uptake 11 fold higher
than the cells treated with CDDP (Fig. 3a). However, the cells
treated with compound 4 displayed a poor platinum uptake,
suggesting that Traniplatin-enhanced internalization could
not be explained exclusively by its increased lipophilicity. We
hypothesized that an active transport that relies on ATP-powered
pumps21 may be involved. In order to reduce the influence of
ATP-pumps in the cancer cells, we evaluated the platinum uptake
of TPT and CDDP at low (4 1C) temperature. Interestingly,
the ratio of platinum internalization between TPT and CDDP
dropped considerably – from 11 fold to 2 fold in A549 cells, and
Fig. 1 (a) IC50 was determined after 72 h treatment in the presence of TPT
(1), CDDP (2), Tranilast (3) and CDDP/Tranilast (1 : 1 ratio) the indicated
cancer cell lines; (b) caspase-3/7 activation as a result of Pt-based drugs
treatment at 10 mM concentration of TPT (1) or CDDP (2) for 24 h; unpaired
t-test (two-tailed) was applied. **p o 0.01.
Fig. 2 (a) logPow of TPT (1), CDDP (2), and 4; (b) platinum uptake in lung
(A549) and colorectal (HT29) cancer cells after TPT (1), CDDP (2), or
compound 4 treatments at 37 1C; (c) platinum uptake in lung (A549) and
colorectal (HT29) cancer cells after TPT (1), CDDP (2), treatments at 4 1C.
Cells were incubated with 10 mM TPT (1), CDDP (2), or compound 4 for
4 h. Platinum levels in the cancer cells were measured using ICP-MS.
****p o 0.0001; **p o 0.01; *p o 0.05.
Fig. 3 Biological activity of TPT (1) and CDPP (2) on macrophages
RAW 264.7. (a and b) Cytotoxicity of TPT (1) and CDDP (2) at (a) 24 h
and at (b) 72 h; (c) IC50 was determined after 24 and 72 h treatment in
macrophage RAW 264.7 cells; (d) platinum uptake of TPT (1) and CDDP (2)
in macrophage RAW 264.7 cells: cells were incubated with 10 mM TPT (1) or
CDDP (2) for 4 h. Platinum levels in the cancer cells were measured using
ICP-MS. ***p o 0.001.
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from 13 fold to 3 fold in HT29 cells – suggesting that TPT could
be internalized through an active transport system (Fig. 3b).
Although the underlying mechanism remains poorly understood,
the correlation between signaling originating from the tumor
microenvironment composed of non-malignant cells surrounding
the cancer cells and the treatment efficiency suggests a key role of
the stromal/immune components in modulating the patients’
response to therapy.22 Following this rationale, we evaluated the
impact of TPT and CDDP on immune cells. Surprisingly, when a
macrophage cell line (RAW 264.7) was treated with TPT and CDDP,
an opposite biological effect was observed. Indeed, CDDP was
found to be more cytotoxic than TPT after 24 and 72 hours
treatment (Fig. 3a–c). Intrigued by this result, we next evaluated
the platinum internalization of TPT and CDDP in macrophages
RAW 264.7. Cells were treated with TPT and CDDP at a concen-
tration of 10 mM. The platinum content was determined following a
4 h treatment. Cells treated with CDDP accumulated higher
quantities of platinum than cells treated with TPT (Fig. 3d). These
results support the hypothesis that an increased intracellular
accumulation of TPT may not only be explained by lipophilicity-
enhanced passive transport, and suggest that other mechanisms –
ATP pumps or specific receptors – could be involved. However,
further investigation will be needed in order to elucidate the
mechanism of the internalization of TPT.
Several sources have reported a positive influence of the
macrophages present at the tumor invasive front on the patients’
prognosis in CRC.23 Khorana et al. have shown that an increased
survival of patients is associated with VEGF-expressing tumor-
associated macrophages (TAM).24 Lackner et al. reported that low
numbers of TAM were associated with the worst prognoses.25 In
addition, Nagorsen and colleagues found that the survival of
patients was significantly improved by increased intra-tumoral
dendritic cell infiltration.26 More generally, a meta-analysis
of 32 studies including 2988 patients suggested that tumor
inflammatory infiltrate was associated with a better prognosis
in patients with colorectal cancer.27 Therefore, the generation
of drugs specifically targeting colorectal cancer cells and avoiding
the immune infiltrate in the tumor may be of great therapeutic
interest. Since TPT displays low cytotoxicity and a reduced
platinum uptake in the macrophage cell line RAW 264.7, we
hypothesized that a similar biological effect could be observed in
patients’ tumors using an ex vivo model.28 We developed a
human tumor explants model, which recapitulates in vitro the
intra-tumoral heterogeneity – the cancer cells and the tumor
microenvironment including inflammatory infiltrate, therefore
allowing the evaluation of treatments that might affect both
cancer epithelial cells and stromal cells. Briefly, tumor explants,
obtained from the surgical specimens of untreated colorectal
cancer patients, were cultured ex vivo in the presence of TPT
(10 mM) or CDDP (10 mM) for 72 h. The cytotoxicity of the
treatment was assessed by detection of the cleaved caspase-3
(a surrogate marker of apoptosis) immunohistochemically in the
explants. Interestingly, immunohistochemical analysis revealed a
prominent nuclear cleaved caspase-3 accumulation in the TPT
10 mM treated explant tumours (Fig. 4a, right panel) compared to the
CDDP 10 mM treated samples (Fig. 4a, left panel). We performed
CD45 immunohistochemical staining to analyse the presence
of inflammatory cells under the above-mentioned conditions.
A hotspot of 15 CD45+ cells was identified in a high power field
in one out of four of the CDDP-treated explants.
However, we observed only a few isolated CD45+ cells in
most of the CDDP 10 mM ex vivo treated explants (Fig. 4b, left
panel). In contrast, the TPT 10 mM treated samples showed
overall increased inflammation related to the tumour epithelium.
In addition, hotspots of 57 and 60 CD45+ cells respectively were
identified in high power fields (Fig. 4b, right panel) in two out
of four of the explants. At a higher chemotherapy concentration
(90 mM), only one hotspot of 5 CD45+ cells was detected in the
explants treated with CDDP, while the explants treated with TPT
showed the occasional presence of CD45+ cells overall and one
hotspot of 10 CD45+ cells (data not shown). Overall, our data
suggest that Traniplatin induces intense intra-tumoral cytotoxicity,
which is associated with increased immune cell infiltrate in
comparison to standard Pt-based chemotherapy (CDDP), suggesting
the decreased cytotoxic activity of TPT against immune cells.
A novel Pt(IV) pro-drug, Traniplatin (TPT, 1) based on Cisplatin
(CDDP, 2) and the marketed drug Tranilast (3), is reported. The
newly synthesized TPT (1) showed enhanced cytotoxicity against
colorectal and lung cancer cell lines triggering caspase-3/7
activation and apoptosis. A higher intracellular uptake of TPT
was measured when compared with CDDP; however, this effect
could not be exclusively associated with the increased lipophilicity
of TPT. An opposite biological effect was observed in macrophages
where the internalization and the cytotoxicity of TPT were
significantly reduced compared to those of CDDP. A similar
effect was detected in CRC patients’ tumor explants treated with
TPT. TPT induces intense intra-tumoral cytotoxicity, which is
associated with an increased presence of intra-tumoral immune
Fig. 4 TPT treated tumor explants derived from CRC patients are char-
acterized by increased apoptosis and the presence of CD45+ immune
cells. Samples were treated in vitro for 72 h with CDDP (10 mM) or TPT
(10 mM) and compared to a non-treated control. Following in vitro treatment,
the samples were processed for further pathological analysis – tissue
fixation, inclusion and sectioning (a and b) immunohistochemical analysis
of representative explants treated ex vivowith CDDP (left panel) or TPT (right
panel). (a) Nuclear cleaved caspase-3 reactivity; arrows point to positive –
apoptotic – cells in the tumor. Scale bars, 50 mm. (b) Cell membrane CD45
reactivity; arrows point to positive – immune – cells in the tumor. Scale bars,
50 mm.
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cell infiltrate, which could be correlated with reduced cytotoxic
activity against immune cells. Previous studies report a robust
correlation between an improved prognosis and the presence
of inflammatory cells in cancers of distinct origin including
colorectal cancer. Hence, decreased chemotherapeutic cytotoxi-
city against CD45+ cells may improve the outcome of treated
colorectal cancer patients. Therefore, TPT increased cytotoxicity
against cancer cells and decreased cytotoxicity against immune
cells could be of immense therapeutic interest.
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